Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sonrotoclax - BeiGene

Next Previous
X
Search
Drug Profile

Sonrotoclax - BeiGene

Alternative Names: BGB-11417

Latest Information Update: 29 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeiGene
  • Developer Amgen; BeiGene
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Acute myeloid leukaemia; Waldenstrom's macroglobulinaemia; Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia
  • Phase II Mantle-cell lymphoma; Multiple myeloma; Richter's syndrome; Waldenstrom's macroglobulinaemia
  • Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes
  • No development reported B-cell lymphoma

Most Recent Events

  • 20 Nov 2024 BeiGene plans a phase I/II trial for Chronic lymphocytic leukaemia (First-line therapy) (PO), in December 2024 (NCT06697184)
  • 14 Nov 2024 Phase-II clinical trials in Chronic lymphocytic leukaemia (Monotherapy, First-line therapy) in USA (PO) (NCT06637501)
  • 14 Nov 2024 BeiGene initiates a phase II trial for Chronic lymphocytic leukaemia (Combination therapy, First-line therapy) in USA (PO) (NCT06637501)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top